"The company has received a warning letter issued by USFDA relating to its Moraiya formulation facility and Ahmedabad API facility (Zyfine) in Gujarat," Cadila Healthcare said in a BSE filing.

"The company is working hard to ensure that the commitments made to USFDA are fully completed. The company will continue to take all necessary steps to ensure that the US health regulator is fully satisfied with our remediation of the above facilities," it added.

Cadila Healthcare said there are no products in the US market which use API (active pharmaceutical ingredient) of Zyfine facility.

"We will respond to USFDA to address the observations within the statutory time permitted in the letter. We are committed to resolve all the issues and revamp our quality systems and processes as the top most priority," the company added.

Reacting to the development, shares of Cadila Healthcare were 15.71 percent down at Rs 324.65 apiece on BSE in the morning trade.

Latest News  from Business News Desk